Copyright
©The Author(s) 2021.
World J Clin Oncol. Feb 24, 2021; 12(2): 103-114
Published online Feb 24, 2021. doi: 10.5306/wjco.v12.i2.103
Published online Feb 24, 2021. doi: 10.5306/wjco.v12.i2.103
Table 4 Progression free survival and overall survival calculated using Wilcoxon rank sum test for comparison
| Overall, n (%) | irAE, n (%) | irAE, Median PFS (mo) | P value | irAE, Median OS (mo) | P value | Endo irAE, n (%) | Endo irAE, Median PFS (mo) | P value | Endo irAE, Median OS (mo) | P value | ||
| Gender | Female | 129 (44) | 41 (45.1) | 6.3 | 0.8977 | 16.3 | 0.4756 | 18 (48.7) | 7.7 | 0.8542 | 17.0 | 0.9495 |
| Male | 164 (56) | 50 (54.9) | 5.7 | 18.5 | 19 (51.4) | 5.7 | 17.0 | |||||
| Race | White | 140 (47.8) | 55 (60.4) | 7.7 | 0.4601 | 20.6 | 0.0237 | 23 (62.2) | 10.4 | 0.2243 | 21.8 | 0.0356 |
| Black | 122 (41.6) | 28 (30.8) | 5.8 | 12.9 | 13 (35.1) | 5.2 | 15.8 | |||||
| Others | 31 (10.6) | 8(8.8) | 2.2 | 16.0 | 1 (2.7) | 6.2 | ||||||
| PDL1 Expression | < 50% | 69 (23.5) | 16 (17.6) | 5.2 | 0.6985 | 14.2 | 0.6468 | 3 (25.0) | 5.2 | 1.000 | 16.5 | 1.0000 |
| > 50% | 32 (10.9) | 14 (15.4) | 6.3 | 16.6 | 9 (75.0) | 6.3 | 15.8 |
- Citation: Peravali M, Gomes-Lima C, Tefera E, Baker M, Sherchan M, Farid S, Burman K, Constantinescu F, Veytsman I. Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World J Clin Oncol 2021; 12(2): 103-114
- URL: https://www.wjgnet.com/2218-4333/full/v12/i2/103.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i2.103